Notably, while KRAS, CDKN2A, and ARID1A mutations are frequently observed in both MBOTs and mucinous ovarian carcinomas [21,58,59], our analysis also identified mutations in ARID1B, SMO, BRIP1, and NF1, as well as amplification of KMT2D and CLIP1 genes, which were not previously associated with MBOTs and MOCs, indicating novel molecular events of these tumors. This evidence concerns the gene SMO and ovarian mucinous adenocarcinoma.